# Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects

> **NCT02869347** · PHASE2 · COMPLETED · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 80 (actual)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** Conestat alfa
- **DRUG:** Sodium chloride 0.9%

## Key facts

- **NCT ID:** NCT02869347
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2018-05
- **Final completion:** 2018-07
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2018-08-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02869347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02869347, "Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02869347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*